June Xu

481 total citations
19 papers, 389 citations indexed

About

June Xu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, June Xu has authored 19 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in June Xu's work include Diabetes Treatment and Management (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Receptor Mechanisms and Signaling (4 papers). June Xu is often cited by papers focused on Diabetes Treatment and Management (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Receptor Mechanisms and Signaling (4 papers). June Xu collaborates with scholars based in China, United States and Switzerland. June Xu's co-authors include Keith T. Demarest, Fuyong Du, Yin Liang, Yi Liu, Tonya Martin, David Polidori, Yasuaki Matsushita, Chiaki Kuriyama, Kenji Arakawa and Kiichiro Ueta and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

June Xu

18 papers receiving 378 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
June Xu China 10 211 172 170 83 48 19 389
Jake Wimberger United States 8 206 1.0× 161 0.9× 187 1.1× 19 0.2× 17 0.4× 9 466
Marc-André Lavoie Canada 9 59 0.3× 92 0.5× 193 1.1× 43 0.5× 45 0.9× 12 385
Jessica D. Dietz United States 8 327 1.5× 146 0.8× 164 1.0× 34 0.4× 5 0.1× 8 496
Takahiro Kawai Japan 9 211 1.0× 164 1.0× 153 0.9× 34 0.4× 13 0.3× 35 409
Je Ryong Kim South Korea 10 58 0.3× 133 0.8× 65 0.4× 93 1.1× 57 1.2× 33 360
Alexandros Patsouras Greece 11 46 0.2× 143 0.8× 59 0.3× 57 0.7× 17 0.4× 26 303
Christian Orlowski Australia 6 30 0.1× 227 1.3× 39 0.2× 63 0.8× 31 0.6× 9 396
Andreas Port Germany 10 218 1.0× 159 0.9× 80 0.5× 92 1.1× 3 0.1× 15 435
Stefan Tschopp Switzerland 4 321 1.5× 297 1.7× 143 0.8× 78 0.9× 6 0.1× 7 584
Satish K. Raut India 11 46 0.2× 340 2.0× 58 0.3× 37 0.4× 7 0.1× 13 522

Countries citing papers authored by June Xu

Since Specialization
Citations

This map shows the geographic impact of June Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by June Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites June Xu more than expected).

Fields of papers citing papers by June Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by June Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by June Xu. The network helps show where June Xu may publish in the future.

Co-authorship network of co-authors of June Xu

This figure shows the co-authorship network connecting the top 25 collaborators of June Xu. A scholar is included among the top collaborators of June Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with June Xu. June Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Yu, Jia, Caicun Zhou, Kai Wang, et al.. (2024). Mefatinib as first-line treatment of EGFR sensitizing mutation-positive non-small-cell lung cancer: A phase III efficacy and biomarker study.. Journal of Clinical Oncology. 42(16_suppl). 8546–8546.
2.
3.
Xiong, Anwen, Lei Jiang, June Xu, et al.. (2021). Blood digital polymerase chain reaction as a potential method to detect human epidermal growth factor receptor 2 amplification in non-small cell lung cancer. Translational Lung Cancer Research. 10(11). 4235–4249. 6 indexed citations
4.
Qi, Jenson, et al.. (2021). GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action. Frontiers in Endocrinology. 12. 4 indexed citations
5.
Yang, Yunpeng, Wenfeng Fang, Yan Huang, et al.. (2021). A phase 2, open-label, multicenter study to evaluate the efficacy, safety, and tolerability of KN046 in combination with chemotherapy in subjects with advanced non-small cell lung cancer.. Journal of Clinical Oncology. 39(15_suppl). 9060–9060. 8 indexed citations
6.
7.
Gong, Jifang, Lin Shen, Dan Liu, et al.. (2020). 810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors. SHILAP Revista de lepidopterología. A485–A486. 4 indexed citations
8.
Xu, Guozhang, Fuyong Du, Gee‐Hong Kuo, et al.. (2020). 5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors. Bioorganic & Medicinal Chemistry Letters. 30(17). 127387–127387. 10 indexed citations
9.
Xu, Guozhang, Michael D. Gaul, Zhi‐Jie Liu, et al.. (2020). Hit-to-lead optimization and discovery of a potent, and orally bioavailable G protein coupled receptor kinase 2 (GRK2) inhibitor. Bioorganic & Medicinal Chemistry Letters. 30(23). 127602–127602. 3 indexed citations
10.
Ji, Dongmei, Jian Zhang, Yiqun Du, et al.. (2020). Preliminary safety, efficacy and pharmacokinetics (PK) results of KN026, a HER2 bispecific antibody in patients (pts) with HER2-positive metastatic breast cancer.. Journal of Clinical Oncology. 38(15_suppl). 1041–1041. 13 indexed citations
11.
Zhao, Hongyun, Yuxiang Ma, Yang Zhang, et al.. (2020). The preliminary efficacy and safety data of KN046 in patients failed on prior immune checkpoint inhibitors therapy.. Journal of Clinical Oncology. 38(15_suppl). 3020–3020. 19 indexed citations
12.
13.
Coward, Jermaine, Vinod Ganju, Kenneth K. Kwong, et al.. (2019). Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors.. Journal of Clinical Oncology. 37(15_suppl). 2554–2554. 14 indexed citations
14.
Kuo, Gee‐Hong, Micheal D. Gaul, Yin Liang, et al.. (2018). Synthesis and biological evaluation of benzocyclobutane-C-glycosides as potent and orally active SGLT1/SGLT2 dual inhibitors. Bioorganic & Medicinal Chemistry Letters. 28(7). 1182–1187. 29 indexed citations
15.
Meegalla, Sanath K., Hui Huang, June Xu, et al.. (2018). Discovery of a novel potent GPR40 full agonist. Bioorganic & Medicinal Chemistry Letters. 28(4). 720–726. 7 indexed citations
16.
Xu, Guozhang, Michael D. Gaul, Gee‐Hong Kuo, et al.. (2018). Design, synthesis and biological evaluation of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as potent and orally active SGLT dual inhibitors. Bioorganic & Medicinal Chemistry Letters. 28(21). 3446–3453. 11 indexed citations
17.
Liang, Yin, Kenji Arakawa, Kiichiro Ueta, et al.. (2012). Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models. PLoS ONE. 7(2). e30555–e30555. 200 indexed citations
18.
Shen, Lan, Yan Zhang, Aihua Wang, et al.. (2007). Synthesis and structure–activity relationships of thiadiazole-derivatives as potent and orally active peroxisome proliferator-activated receptors α/δ dual agonists. Bioorganic & Medicinal Chemistry. 16(6). 3321–3341. 21 indexed citations
19.
Matthews, Jay M., Xiaoli Chen, Ellen V. Cryan, et al.. (2007). Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARα agonists. Bioorganic & Medicinal Chemistry Letters. 17(24). 6773–6778. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jake Wimberger Breakdown of academic impact, for papers by Marc-André Lavoie Breakdown of academic impact, for papers by Jessica D. Dietz Breakdown of academic impact, for papers by Takahiro Kawai Breakdown of academic impact, for papers by Je Ryong Kim Breakdown of academic impact, for papers by Alexandros Patsouras Breakdown of academic impact, for papers by Christian Orlowski Breakdown of academic impact, for papers by Andreas Port Breakdown of academic impact, for papers by Stefan Tschopp Breakdown of academic impact, for papers by Satish K. Raut
Rankless by CCL
2026